Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 1-1, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 10-10, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 101-101, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 103-103, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 105-105, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 106-106, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 107-107, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 108-108, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 109-109, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 11-11, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 110-110, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 111-111, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 112-112, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 113-113, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 114-114, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 115-115, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 116-116, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 118-118, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 119-119, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 120-120, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 121-121, July 2026.

Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them?

In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days.

Among 38 patients who received CAR T-cell therapy for refractory or relapsed B-cell lymphomas, lymphoma-free survival at 10 years was 32% for large B-cell lymphomas and 47% for follicular lymphoma.

Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,...

The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences.

A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing.

Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion.

Among patients with moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but with a higher risk of bleeding.

Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood.

This review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement.

A 74-year-old man with a recent orthotopic heart transplantation was admitted to the hospital because of persistent pancytopenia that resulted in serial transfusions of packed red cells. A diagnosis was made.

Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ...

Hemorrhagic shock remains the leading cause of preventable death after injury.1 Over the past two decades, early administration of blood products has transformed care for patients with bleeding. The Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial2 established that among patients with severe trauma and...

The clinical benefits of checkpoint inhibitors in the treatment of cancer often wane. A preclinical study points to a potential strategy for a more durable effect.

A 66-year-old man with a history of Crohn’s disease treated with long-term adalimumab presented with fever and swelling of both knees. Analysis of a biopsy sample of the left knee synovium showed an atypical T-cell infiltrate.

In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used.

In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo.

Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events.

The authors report the results of interim analyses of two phase 3 studies of exa-cel, a gene-edited cellular therapy, in children with transfusion-dependent β-thalassemia or sickle cell disease.

The authors review current strategies for anticoagulation reversal in major bleeding events or urgent surgery as well as specific antidotes, limits of available evidence, thrombotic risks, unmet therapeutic needs, and ongoing research.

Technological innovations in health care—including artificial intelligence (AI)—have rapidly transformed core components of oncology care. With public health-care systems under substantial financial strain, advancing digital technology has become a game-changing tool in modern oncology workflows. Such technology offers the potential for more precise, efficient, and cost-effective interventions and could help to revolutionise clinical trials, cancer diagnosis, treatment, and health outcomes; reduce waiting times; and ease pressure on health-care services.

Breast radiotherapy is an integral component of breast cancer care to reduce locoregional recurrence.1 Historically, radiotherapy was delivered daily in 25–30 fractions over 5–6 weeks. Radiobiological and technological advances have enabled hypofractionation: shorter courses with larger doses per fraction achieve similar tumour control while reducing late tissue effects through reduced total dose.2 This approach was established in the first generation breast hypofractionation trials,3,4 in which the 3-week regimen (40 Gy in 15 fractions or 42·5 Gy in 16 fractions) matched the tumour control of conventional fractionation with less late tissue effects.

Radioligand therapy, commonly referred to as peptide receptor radionuclide therapy (PRRT), is an established and effective treatment for patients with advanced gastroenteropancreatic neuroendocrine tumours who have progressive disease after previous systemic therapy.1 Treatment selection in patients with progressive advanced gastroenteropancreatic neuroendocrine tumours is multifactorial and guided by primary site, hormonal functionality, symptom burden related to tumour volume, extent of metastatic disease, histological grade, and patient preference.

The Lancet Oncology Commission on the cancer workforce1 presents a stark analysis of an impending global health catastrophe. The Commission projects a workforce shortage of nearly 100 million individuals by 2050. This shortage directly correlates with a widening survival gap between high-income countries (HICs) and low-income and middle-income countries (LMICs). By 2050, Africa's 5-year net survival rate could be nearly half that of HICs, a disparity directly linked to the lack of qualified health professionals.

The Lancet Oncology Commission on the cancer workforce1 makes a case that governments, funders, and policy makers can no longer ignore. It elegantly reframes workforce investment—not as a development aspiration but as an economic imperative. However, a compelling case and a complete one are not always the same thing.

The Lancet Oncology Commission on the cancer workforce1 arrives at a moment of mounting pressure on cancer systems worldwide. However, the workforce crisis is not only a question of numbers, it reflects deeper challenges in how care is organised, delivered, and experienced. Patients, families, and caregivers continue to describe systems that are fragmented, impersonal, and poorly equipped to care for the person beyond the disease. At the same time, burnout and moral injury among oncology professionals are rising, further deepening the workforce crisis.

Workforce disparities in cancer care represent one of the most profound and persistent inequities in global health, with low-income and middle-income countries (LMICs) bearing a disproportionate share of cancer mortality. While high-income countries (HIC) maintain a relatively high number of specialists involved in cancer care, many LMICs struggle with major shortages. This inequality is notably severe for diagnostic specialists, who are 15 times more prevalent in HICs than in low-income regions.

The Lancet Oncology Commission on the cancer workforce1 documents a global crisis in the cancer workforce defined by chronic undersupply, accelerating demand, and health systems increasingly unable to recruit and retain the specialists they need. The UK offers a pointed illustration of how domestic policy choices can compound this challenge.

The Lancet Oncology Commission on the cancer workforce1 is a timely and important examination of the future unmet need for cancer health professionals, and the devastating fiscal and human cost of inaction. In many settings, this crisis is not looming; it has already arrived.

Abdurrahman Hajeer and colleagues published findings from an observational study in which 708 948 cancers were estimated to have required brachytherapy across 185 countries in 2022 (3·8% of incident cases).1 Assuming 218 cases per centre annually, 2246 additional centres would be required by 2050. These findings highlight major inequities in access but do not determine priority setting for cancer control resources.

We read with great interest the OligoPanc consensus by Carl-Stephan Leonhardt and colleagues.1 We congratulate the authors on this landmark interdisciplinary work, which represents the first international effort to standardise the definition of oligometastatic pancreatic ductal adenocarcinoma, and will help harmonise future clinical trials.

We thank Hector Prudhomme and colleagues for their interest in our Article describing a consensus definition of oligometastatic pancreatic ductal adenocarcinoma.1 Para-aortic lymph nodes are an important site of metastasis in pancreatic ductal adenocarcinoma and were therefore explicitly addressed, both in the Delphi process and in vignette three. Although 27 (82%) of 33 respondents to vignette three considered it oligometastatic pancreatic ductal adenocarcinoma, only 32 (56%) of 57 in the Delphi consensus classified para-aortic lymph node metastasis as oligometastasis, thereby meaning that the predefined 75% or greater consensus threshold was not reached.

We read with interest the systematic review and meta-analysis by Alexander H R Varey and colleagues1 assessing the potential survival benefit of sentinel node biopsy (SNB). We also recognise author John F Thompson for a long and accomplished career that successfully established SNB as a routine part of melanoma diagnostics.

We thank Dirk J Grunhagen and colleagues for their interest in our systematic review. We agree that minimising bias is crucial in such studies. Although individual patient data were not available, the Review was rigorously conducted to minimise residual confounding and selection bias through careful study design and appropriate analyses.

Morgans AK, Haresh KP, Jievaltas M, et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2026; 27: 614–24—In this Article, the third sentence of the last paragraph of the Results section should have read “The most common grade 3–4 adverse events were hypertension (19 [4%] of 445 patients who received darolutamide vs eight [4%] of 221 patients who received placebo), anaemia (14 [3%] vs eight [4%]), and aspartate aminotransferase increase (ten [2%] vs one [<1%]).” This correction has been made to the online version as of June 1, 2026.

Widder J, Bol GM, Simek I-M, et al. Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium. Lancet Oncol 2026; 27: e238–47—In this Policy Review, the table headings should have read “Frequency”. In the Declaration of interests section, statements have been corrected for Helena M Verkooijen and Luca Visani. These corrections have been made to the online version as of June 1, 2026.

Clinicians in England do not have the capacity or headspace to do the innovation needed to deliver the Government's National Cancer Plan, a think tank has warned.

In Thailand, particularly in the northern provinces of the country (eg, Chiang Mai), sustained air pollution, mainly due to persistent wildfires and burning of agricultural waste by farmers, has led to a thick cloud of grey haze and substantial exposure to PM2·5, triggering surges in pollution-related illnesses including cancer.

Almost a fifth of the US population are exposed to potentially cancer-causing nitrates through their drinking water, according to a recent analysis by the Environmental Working Group (EWG).

One in five cancer clinical trials in the USA fail due to insufficient patient enrolment, according to a report from the American Cancer Society Cancer Action Network. Recruitment challenges are pushing researchers overseas, where recruitment is often faster and less expensive, while many eligible US Americans—especially older adults, people from racially minoritised or minority ethnic populations, residents of low-income rural communities, and members of Indigenous communities—cannot afford to participate in potentially life-saving trials, largely because of travel expenses.

On April 27, 2026, US radiation oncologists visited Capitol Hill to tell legislators that the recent policy changes in Medicare have threatened the sustainability of community cancer clinics in the country, as latest data suggested significant economic distress across the field.

David Krug (University Hospital Schleswig-Holstein, Kiel, Germany) presented the first results from a randomised controlled trial showing a progression-free survival benefit from metastasis-directed therapy for patients with oligometastatic breast cancer. In the randomised controlled OLIGOMA trial, patients were randomly assigned to systemic therapy (n=44) or systemic therapy plus stereotactic body radiotherapy (SBRT) to metastatic lesions (n=43). Co-primary endpoints were progression-free survival and quality of life at 12 weeks.

Gaps in patient data reported to the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database by some rural, safety-net, and community hospitals could skew cancer rates and survival outcomes in studies of some of the most vulnerable patient populations. Patients treated at facilities not accredited by the American College of Surgeons Commission on Cancer were two to three times more likely to have missing clinical data in SEER patient records than those treated at Commission on Cancer-accredited centres, researchers reported.

Lung cancer is the leading cause of cancer deaths, causing approximately 1.8 million deaths worldwide.1 Screening with low-dose CT (LDCT) has been shown to significantly reduce lung cancer-specific mortality among populations at high-risk by 20–26%.2 National lung cancer screening programmes have been implemented in several countries and will be introduced in Germany in 2026. Despite these advances, population-level implementation fails to adequately reach those at highest risk;3 globally, lung cancer screening programmes face persistent challenges in achieving equitable access across racial, ethnic, geographic, and socioeconomic groups.

Aglatimagene plus valacyclovir was associated with longer disease-free survival than placebo plus valacyclovir when added to standard of radiotherapy for the treatment of localised prostate cancer, offering a meaningful benefit without increasing clinically significant toxicity.

Long-term follow-up confirms that 26 Gy in five fractions over 1 week is safe and efficacious for adjuvant radiotherapy to the breast or chest wall, supporting its use as a standard of care. Efficacy data for this schedule in the axillary nodal radiotherapy setting are reassuring; however, sample size limits precision of estimation for this subgroup on its own.

Using sunitinib as an internal control, our results show clinically significant antitumour efficacy of [177Lu]Lu-dota-tate in pretreated, progressive, somatostatin receptor-positive, metastatic pancreatic neuroendocrine tumours, and a better quality of life during the treatment phase. Late adverse events were reported in the [177Lu]Lu-dota-tate group that might affect the tolerance of subsequent lines of treatment.

Long-term follow-up supports the safety and local control of SABR for non-surgical patients with renal cell carcinoma, with no observed local recurrences or cancer-related deaths in this cohort, which had predominantly T1b disease or higher.

This pooled analysis from two clinical trials of SABR in patients with larger primary kidney tumours unsuitable for surgery supports evidence of long-term local control and low rate of severe adverse events. These results support further investigation through a randomised trial comparing SABR with surgery in select operable patients.

MRI-guided adaptation for glioblastoma enables margin de-escalation and resulted in a low rate of marginal failure. A randomised trial comparing this technique to a standard large-margin radiotherapy approach will establish whether toxicity and quality-of-life improvements can be realised.

The pandemic's greatest impact was during the first few months of societal lockdowns in 2020 when barriers in access to health care were greatest. Further research is needed to understand whether patients with a missed diagnosis were diagnosed at a later date and if they presented at a later stage.

This breast radiotherapy dosimetry audit shows the feasibility of high-quality large-scale, real-world dosimetric collection and evaluation across the NHS in England. Heart and lung doses predominantly met constraints and were comparable to international benchmarks. However, dosimetric variation existed between centres, particularly in volumetric-modulated arc therapy planning, identifying opportunities for quality improvement.

The shortage of well-trained personnel to deliver cancer care and conduct research remains a major obstacle to reducing disparities in cancer survival between high-income countries and low-income and middle-income countries (LMICs). This Commission set out to provide actionable guidance for strengthening the global cancer workforce with an emphasis on reducing these disparities. To better understand the extent of the rising global cancer burden and the resulting workforce needs, we modelled the current and future global landscape of 17 common cancers and 18 workforce personnel types.

Pediatric cancer survival has continued to improve. However, differences persist by age, sex, race and ethnicity, economic status, geography, and cancer type.

Postoperative anlotinib plus radiotherapy demonstrated clinically meaningful activity with a manageable safety profile in patients with unmethylated MGMT glioblastoma (Chinese Clinical Trials Registry identifier: ChiCTR2000040116).

In patients with very high‐risk NMIBC, magnetic resonance imaging–derived radiomic phenotypes can be used to stratify responses to immunochemotherapy and capture functional immune states. Noninvasive radiomic profiling may guide precision treatment selection in patients who are unfit for radical cystectomy, and prospective validation is warranted before clinical adoption.

TB + iSB met the prespecified noninferiority criterion for csPCa detection relative to TB + SB and may represent a promising core‐reduction strategy in transperineal MRI‐guided biopsy, although the full protocol still provided additional contralateral information.

The addition of olaparib to radium‐223 was not associated with significant detriment to PROs or pain, which supports the tolerability of this combination.

Selinexor combined with azacitidine or ruxolitinib showed encouraging efficacy with a manageable safety profile in patients with MDS/MPN.

This analysis of 2 cohort studies and a mouse model examined the association of clonal hematopoiesis of indeterminate potential with cardiotoxic effects in patients with breast cancer receiving trastuzumab.

This systematic review and meta-analysis assesses the prognostic value of pretreatment magnetic resonance imaging (MRI) parameters for oncological outcomes in men undergoing radical prostatectomy.

This cohort study examines characteristics and context of adolescent and young adult patients with cancer who use medical assistance in dying in Alberta, Canada.

This randomized clinical trial evaluates the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous non–small cell lung cancer.

This population-based cross-sectional analysis quantifies adult T-cell leukemia/lymphoma incidence by race, ethnicity, and detailed country of birth in the US.

This systematic review and meta-analysis examines outcomes of local therapy without systemic therapy for radiorecurrent prostate cancer.

This cohort study examines subsequent treatments and outcomes for patients with non–small cell lung cancer after pembrolizumab discontinuation following 2 years of therapy.

This cohort study compares the AQUILA trial inclusion criteria and the 2/20/20 risk stratification model definitions for identifying individuals with smoldering multiple myeloma at high risk of progression.

This genomic profiling study describes the molecular architecture of 1104 prospective consecutive meningioma samples from one academic medical center.

This cross-sectional study examines trends in colorectal cancer mortality rates among individuals aged 25 to 49 years by educational attainment, as a marker of socioeconomic status.

This cohort study examines the associations of minimally invasive surgery, intraoperative capsule rupture, and overall survival among patients with stage I ovarian cancer.

This secondary analysis of a nonrandomized clinical trial assesses long-term survival and genomic variants associated with therapeutic resistance in patients receiving maintenance rucaparib with

This cross-sectional study uses data from the 2011-2020 US National Health and Nutrition Examination Survey to evaluate trends and patterns in receipt of lifestyle advice and ongoing lifestyle practices for weight control, physical activity, and dietary intake among cancer survivors.

A 60-year-old woman presented with progressive right lower extremity radiculopathy and numbness, a pigmented skin lesion on the right side of the chest, and right ankle jerk reflex. Magnetic resonance imaging of the lumbar spine revealed multiple intradural, contrast-enhancing lesions. What is your diagnosis?

This Viewpoint describes how parents of young adults with cancer navigate myriad psychosocial challenges related to their child’s specific life stage, and how these necessitate specialized support that may currently be overlooked in young adult cancer care.

This Viewpoint examines the underutilization of glucagon-like peptide-1 receptor agonists and bariatric surgery in survivors of cancer.

This Viewpoint discusses food insecurity among individuals with cancer and proposes strategies to address this issue, including routine screening, advocating for policy reform, and connecting patients with community resources.

This Viewpoint discusses the curative/palliative dichotomy used to describe the framework of cancer care and how it may affect care trajectories, patient-centered communication, shared decision-making, and advance care planning.

This essay describes the author’s grieving process with the death of their father.

June 19, marks World Sickle Cell Day, with the 2026 theme focusing on closing the survival gap and a push towards a universal cure. 20 years have passed since the WHO recognised sickle cell disease as a global health problem, and although some progress has been made, there is clearly still substantial work to be done to improve outcomes for those living with the disease around the world.

The diagnosis of primary CNS lymphoma has traditionally relied on stereotactic brain biopsy, while cytological analysis of cerebrospinal fluid (CSF) or vitreous humour is diagnostic in only a minority of patients.1 Although essential for histopathological confirmation, brain biopsy carries inherent risks, with mortality rates ranging from 0·8% to 2·2%, and might cause substantial delays in treatment initiation.1 Consequently, the development of reliable, less invasive diagnostic approaches has become a major objective in the management of primary CNS lymphoma.

Bone marrow examination is integral to the diagnosis and classification of myeloproliferative neoplasms, but is invasive, can be technically challenging, and is not always immediately feasible. Marie Donzel and colleagues present the Fibrosis Prediction in Bone Marrow using Artificial Intelligence (FIBOM-AI) model,1 a machine learning model trained to predict grade 2–3 bone marrow fibrosis using only age and routine complete blood count (CBC) parameters. Developed from a multicentre cohort using data from 1995 patients with a suspected or established myeloproliferative neoplasm across 13 French centres, and evaluated with both external and prospective validation, this study offers a practical example of how artificial intelligence (AI) can extract insights from routine, inexpensive laboratory data.

Sickle cell disease is one of the most common severe hereditary disorders worldwide. More than 500 000 infants are born with sickle cell disease each year, the majority in sub-Saharan Africa, where early diagnosis and comprehensive care remain limited.1 Advances in neonatal screening and infection prevention have improved survival, but this success has also exposed the growing lifetime burden of cerebrovascular disease.1 Stroke is a leading cause of morbidity, cognitive impairment, and disability in sickle cell disease.

We write as an international group of qualitative researchers working within haematology. We commend Prasanna Ananth and colleagues for their expert recommendations on conducting and appraising qualitative research, including five pillars that support best practice in qualitative studies.1 Quantitative research can tell us what and how much, but qualitative and mixed methods studies help explain why. These approaches are essential for creating and evaluating interventions that work in real-world contexts.

“Where is Talal?” one of the fellows asked.“Probably in the library” another replied with a chuckle.

Chronic lymphocytic leukaemia is often described as indolent—a leukaemia that unfolds slowly, sometimes over decades. In older adults, it behaves less like an acute malignancy and more like a chronic companion. Many patients are diagnosed incidentally and require no immediate therapy. The biology might be calm but the lived experience rarely is.

When Ayako Arai was at medical school in the late 1980s, she became fascinated with the “extraordinary beauty” of blood cells under a microscope. At the time, haematopoietic stem-cell transplantation (HSCT) was just becoming established and the concept of molecular targeted therapy beginning to emerge.

“You Look Fine” begins with LA-based comedian Jared “J” Snow trying a bit of boxing. His trainer holds the mitts and calls the combinations. Jab, right, hook, right, roll, finish with another right. J lands punches, moves competently around the ring, and rests when the bell sounds. After three rounds, he starts feeling discomfort in his chest, so he stops training and goes home to bathe in Epsom salts and swallow some painkillers. He hopes this will be enough to forestall a sickle cell crisis.

Adverse events were few, probably due to organ sparing by total marrow and lymphoid irradiation. Total marrow and lymphoid irradiation 2000 cGy could be safely delivered in combination with high-dose etoposide and cyclophosphamide. The regimen was associated with encouraging 2-year progression-free survival rates.

In this prospective, multicentre cohort of patients with suspected primary CNS lymphoma, we validated the high diagnostic value of MYD88, IL-10, and CXCL13. Results should be interpreted within the full clinical context and with caution, as the diagnostic algorithm and decision tree were derived within the same cohort. In selected clinical scenarios and with further validation of these results, combined CSF biomarker testing might support non-invasive diagnostic decision making and reduce reliance on brain biopsy.

This study showed a high prevalence of post pulmonary embolism syndrome in children with pulmonary embolism. Different clinical factors can contribute, including psychological distress factors and physical limitations, emphasising the need for comprehensive, multidisciplinary care.

FIBOM-AI can be reliably used as a triage and prioritisation tool to support timely bone marrow evaluation or provide complementary risk assessment when bone marrow biopsy is not immediately feasible.

Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and Australia worked together on behalf of the EBMT Practice Harmonisation and Guidelines Committee to delineate a pragmatic diagnostic framework and issue guidance for downstream clinical management for DDHN. The team met on Sept 18–19, 2025, in Berlin, Germany, to discuss the definition, molecular insights, treatments, and donor outcomes for DDHN after an intensive review of the literature.

Sickle cell disease is a haematological disorder marked by recurrent events and progressive organ dysfunction, yet a standardised framework to assess disease severity is lacking. We developed a novel US-based severity grading system through identification of sickle cell disease-related complications mapping all to the Common Terminology Criteria For Adverse Events and applying a five-level severity scale. A modified Delphi process involving 29 US-based sickle cell disease experts was conducted over three virtual rounds (from Oct 20 to Nov 8, 2023; from June 26 to Aug 1, 2024; and from Nov 6, 2024, to Jan 7, 2025), with the use of a 9-point Likert scale ratings and iterative feedback.

An 83-year-old woman presented to our haematology department in June, 2025, with a 3-month history of palpable cervical lymphadenopathy and splenomegaly. Contrast-enhanced CT revealed enlarged cervical, axillary, inguinal, and visceral lymphadenopathy. A biopsy of a cervical lymph node verified a diagnosis of stage IV angioimmunoblastic T-cell lymphoma (AITL; appendix pp 3–4). Immunohistochemistry showed atypical T cells positive for CD3, CD4, CD10, CD30, ICOS, BCL6, and PD1. In-situ hybridisation for Epstein–Barr virus (EBV)-encoded RNA (EBER) testing was negative (appendix p 7).

Understanding of the pathophysiology of cold agglutinin disease (CAD) has serially led to the use of B-cell–targeted therapies such as rituximab-based regimens and, more recently, complement pathway inhibitors. CAD arises through formation of immunoglobulin M autoantibodies, which bind the I antigen on red cells, triggering agglutination and also complement activation resulting in extravascular hemolysis. Under stress conditions, complement activation is amplified and intravascular hemolysis becomes a dominant clinical feature. In this Perspective, Fattizzo, Miyakawa, and Broome summarize key data and provide their expert opinion as to when to use rituximab, rituximab-based chemoimmunotherapy, or sutimlimab and other complement pathway inhibitors.

Bussel, Hirshman, and Kapur review the diagnosis, pathophysiology, and management of anti–human platelet antigen 1a (HPA-1a)–mediated fetal-neonatal alloimmune thrombocytopenia as understood in 2026. By integrating data on evolving diagnostic strategies, their synthesis encourages the field to reconsider current approaches and may help improve outcomes for affected pregnancies and newborns.

The use of haploidentical donors for allogeneic hematopoietic stem cell transplantation has greatly expanded its application, enabled by advances in graft-versus-host disease (GVHD) prevention, primarily the use of antithymocyte globulin (ATG) or posttransplant cyclophosphamide (PTCy). Yang and colleagues report the first randomized phase 3 trial to directly compare PTCy, ATG, and their low-dose combination for preventing GVHD after haploidentical peripheral blood stem cell (PBSC) transplantation for acute myeloid malignancies, finding no significant differences in any GVHD or survival end points across the 3 strategies. While several questions remain unresolved, these important data validate the use of either agent or the low-dose combination in practice.

High CD49d expression identifies patients with more aggressive chronic lymphocytic leukemia (CLL) and poor survival, but the functional basis for this is speculative. Polcik and colleagues confirm that CD49d is necessary for CLL cell homing to the bone marrow and for localization in the secondary lymphoid organs and that its expression levels are associated with distinct bone marrow infiltration patterns in patients. They also reveal its importance in controlling B-cell receptor (BCR) responsiveness by organizing the actin cytoskeleton and regulating immune synapse formation, thereby suggesting that it could be a therapeutic target worthy of future investigation.

In multiple myeloma (MM), transcriptional regulators such as MYC, interferon regulatory factor 4 (IRF4), and MAF are important. In a search for potential therapeutic targets, Gómez-Echarte et al integrated functional genomics, mechanistic studies, and clinical data to identify IRF2 as an essential transcription factor in MM. IRF2 links oncogenic transcription to repression of necroptosis and disease dissemination and is an independent prognostic biomarker that adds discriminatory power to current standard algorithms for prognostication.

It is now appreciated that most cases of acute myeloid leukemia (AML) have clonal heterogeneity, and, as a result, the relationships between genotype, immunophenotype, and treatment outcome can be confusing. Drucker et al used single-cell analyses of 43 samples from patients with NPM1-mutated AML to reveal that comutations in epigenetic regulators shape immunophenotype while mutations in signaling pathways increase clonal complexity. Such insights reinforce the need for physicians to adapt treatment paradigms to accommodate the limitations in prediction afforded by standard genotyping.

Iron is essential, but at high levels it can be toxic, with each cell type having distinct requirements and mechanisms for utilizing the metal. Using murine models of iron overload, Sighinolfi et al report that iron damages mitochondria in hematopoietic stem cells (HSCs), leading to fewer active mitochondria, oxidative stress, and upregulated glycolysis. Restoring mitochondrial function by targeting reactive oxygen species improved the quiescence and self-renewal of HSCs in a mouse model of β-thalassemia. These findings further encourage efforts to reduce iron loading in thalassemias, myelodysplasias, and transfusional iron overload states.

Traumatic brain injury (TBI) disrupts the blood brain barrier (BBB) and injures the microvasculature, causing bleeding, hyperfibrinolysis, and sometimes consumptive coagulopathy, yet the evidence for empiric use of platelet infusions is not supported by evidence in the absence of severe thrombocytopenia. Trivedi and colleagues studied a murine model of traumatic brain injury, showing that freeze-dried platelets preserve the BBB, dampen neuroinflammation, improve cerebral blood perfusion, and reduce intracerebral hemorrhage. These provocative results warrant early phase clinical trials with selected patients with serious brain trauma.

New England Journal of Medicine, Volume 394, Issue 24, Page 2429-2439, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2395-2406, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2419-2428, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2407-2418, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2487-2488, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2481-2483, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2477-2479, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2474-2476, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2473-2474, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2459-2459, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2390-2392, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2385-2387, June 25, 2026.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

Existing agents such as statins and beta-blockers showed cardioprotective properties in select subgroups, but more treatments are needed to protect against heart failure in patients receiving treatment for cancer, according to findings from a systematic review and meta-analysis presented at the...

In a French phase I/II trial (TROPHAMET) reported in JAMA Oncology, You et al found that first-line avelumab plus methotrexate was associated with high efficacy in patients with low-risk gestational trophoblastic tumors.

In an analysis reported in the Journal of Clinical Oncology, Wilson et al found that prophylactic high-dose methotrexate does not provide significant benefit in reducing central nervous system (CNS) relapse in patients with ultra–high-risk large B-cell lymphoma (LBCL).

On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) for two indications in adults with triple-negative breast cancer (TNBC).

Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment. The new...

A large real-world study conducted across six Asian countries suggests that a blood-based multi-cancer early detection (MCED) test may accurately identify multiple cancer types in routine clinical practice, including cancers for which no standard screening programs currently exist. The research was ...

Treatment with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant produced substantial clinical benefits in Asian patients with PIK3CA-mutated, hormone receptor–positive (HR-positive), HER2-negative, endocrine-resistant advanced breast cancer, according to a subgroup...

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD). The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting,...

A HER2-targeted regimen produced high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from a single-arm phase II neoadjuvant trial conducted in China. The research was highlighted in a media briefing ahead of the...

Early integration of palliative, or supportive, care at the time of breast cancer diagnosis improved quality of life more than on-demand palliative care in a randomized trial of patients in India. The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting, taking...

On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor (HR)-positive, HER2-positive locally advanced or...

In an interim analysis of a Chinese phase III trial (FCN-437c-III201) reported in JAMA Oncology, Yuan et al found that the addition of the novel CDK4/6 inhibitor fovinaciclib to aromatase inhibitor therapy was associated with significant improvement in progression-free survival in the first-line...

Educational gaps in cardio-oncology training have been identified in the results of an international survey presented at the European Society of Cardiology (ESC) Congress 2026.

In an interim analysis of a phase III trial (MonumenTAL-3) reported in The New England Journal of Medicine, Mina et al found that the combinations of talquetamab with daratumumab/pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) improved progression-free survival vs...

Researchers have found that wearable devices may help clinicians detect cytokine-release syndrome—a common and potentially serious side effect of chimeric antigen receptor (CAR) T-cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma.  

In a Chinese phase III trial (AENEAS2) reported in The Lancet Oncology, Li et al found that the combination of aumolertinib with chemotherapy significantly improved progression-free survival vs aumolertinib alone in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC).

In a long-term individual patient-level pooled analysis reported in the Journal of Clinical Oncology, Gandini et al found that low-dose tamoxifen was associated with good outcomes in patients with noninvasive breast neoplasia.

Researchers have developed and validated an artificial intelligence (AI)‒assisted volumetric response criteria for assessing response in pleural mesothelioma. The AI-backed criteria outperformed both humans and standard international Response Evaluation Criteria in Solid Tumors (RECIST) criteria,...

In a Chinese phase I dose-escalation and dose-expansion study reported in the Journal of Clinical Oncology, Qi et al found that guanylyl cyclase 2C (GUCY2C)-targeted chimeric antigen receptor (CAR) T-cell therapy had an “acceptable” safety profile and was active in patients with previously treated...

In an Australian phase III noninferiority trial reported in The Lancet Oncology, Buteau et al found that use of gallium-68–labeled PSMA-11 (Ga-68–PSMA-11) positron-emission tomography/computed tomography (PET/CT) could improve the pathway of diagnosis of prostate cancer in men with clinical...

In an interim analysis of a phase III trial (SUCCESOR-2) reported in The Lancet, Dimopoulos et al found that the addition of the cereblon E3 ligase modulator mezigdomide to carfilzomib/dexamethasone significantly improved progression-free survival in previously treated patients with relapsed or...

The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic...

The American Gastroenterological Association (AGA) recently reported that among expanding options for colorectal cancer screening, colonoscopy remains the AGA's top recommendation.

In an individual patient analysis reported in the Journal of Clinical Oncology, Moon et al found that treatment of early-stage hepatocellular carcinoma (HCC) with external-beam radiation therapy (EBRT) was associated with survival outcomes comparable to other treatment modalities such as surgical...

Results from the phase III EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab, regular interval durvalumab) regimen, with or without the targeted therapy lenvatinib, can slow the cancer’s...

Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known.

A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort.

All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators.

In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock.

Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP.

The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system.

NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs.

Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source.

A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care.

To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care.

Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success.

Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC).

Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery.

In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU.

Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening.

Modern oncology has built highly efficient pathways for patent-protected innovation, but no equivalent machinery for evaluating and developing promising off-patent therapeutics. Herein, we frame ‘open-source oncology’ as a parallel public-interest infrastructure to test, authorize and implement credible generic agents. Designed to translate ownerless evidence into standard-of-care treatments, this framework applies the same scientific seriousness devoted to proprietary drugs, decoupling clinical value from commercial ownership.

Over the past decades, cancer epidemiology trends have substantially shifted in China, with a rapid increase in incidence of cancers that are most common in high-income countries and a substantial decline in incidence of cancers historically prevalent in China. The authors of this Review provide an overview of cancer epidemiology in China, a major contributor to global cancer burden, and discuss national cancer control policies and targets.

The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose.

Three antibody–drug conjugates (ADCs) are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 and tisotumab vedotin for cervical cancer (independent of tissue factor expression). The authors of this Review discuss current priorities in the clinical development of ADCs for gynaecological cancers, such as identifying novel targets, understanding mechanisms of resistance and sequencing strategies, and managing toxicities, highlighting key advances and future opportunities.

Teclistamab monotherapy improves survival in RRMM

Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia

Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma

Adjuvant selpercatinib shows benefit in patients with NSCLC

Annals of Internal Medicine, Volume 179, Issue 6, Page 765-772, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 773-784, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 785-793, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 794-803, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 804-811, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 812-822, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 823-834, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 842-856, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 857-867, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 835-838, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 839-841, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 868-873, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 874-884, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 885-888, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 889-891, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 892-894, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 895-897, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 898-899, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 900-901, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 902, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 903-904, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 905-906, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 908-911, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 911-914, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 915-916, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 914, June 2026. <br/>

Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities.

As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”

Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.

Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.

While falling short of statistical significance, Incyte and Mirum Pharmaceuticals’ ALK2 inhibitor showed a “clear benefit” in reducing abnormal bone formation in a Phase 2 study of fibrodysplasia ossificans progressiva.

Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.

Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.

The positive ADHD data for Otsuka Pharmaceutical’s centanafadine is good news in what has of late been a mixed bag for the neuropsychiatric space.

Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.

Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.

Results for Definium Therapeutics psychedelic candidate for major depressive disorder “exceeded expectations,” according to Stifel, while Jefferies called the efficacy data “profound.”

With a one-time dosing profile, Intellia Therapeutics’ gene editing asset could be “paradigm-shifting” for hereditary angioedema, according to Jefferies. The biotech anticipates market approval next year.

Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.

Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.

The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.

While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.

The positive ADHD data for Otsuka Pharmaceutical’s centanafadine is good news in what has of late been a mixed bag for the neuropsychiatric space.

Policymaking at FDA has been anything but business as usual under the Trump administration, but former regulators cite the agency’s new investigational new drug pilot program as a sign of normalcy.

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We explore the UK biotech ecosystem: from the Golden Triangle’s evolving role to the challenges of scaling companies, unlocking pension capital and staying globally competitive.

Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities.

Recent BioSpace industry conference conversations point to sponsors pushing earlier on safety, quality and performance data, leading to demand for nitrosamine analysis, IVRT/IVPT and microbiome database capabilities.

Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.

Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.

Among the health department’s efforts is an expedited investigational new drug pilot program that would leverage collaborations with U.S. research institutions to reduce early trial timelines by as much as 12 months.

Results for Definium Therapeutics psychedelic candidate for major depressive disorder “exceeded expectations,” according to Stifel, while Jefferies called the efficacy data “profound.”

As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”

On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC). 

On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.

On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.

On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.

On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.

On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. 

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 

On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024. 

On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.

On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).

J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1602-10. doi: 10.1097/00004583-199612000-00011.
Brown RA, Lewinsohn PM, Seeley JR, Wagner EF

Pan Afr Med J. 2026 Mar 26;53:144. doi: 10.11604/pamj.2026.53.144.51276. eCollection 2026.
Sadaoui I, Sadaoui I, Joutei HAH, Benomar H, Nadifi S

Cell. 2026 Jun 22:S0092-8674(26)00636-7. doi: 10.1016/j.cell.2026.05.036.
Lei G, Lu Z, Xu Z, Braun C, Huo D, Gao J, Tan L, Hong T, Wu S, Sun M, Zhao X, Li Q, Chen X, Yan Y, Lee H, Mao C, Zhuang L, Ku LT, Puebla N, Barsoumian H, Yao J, Hong L, Zhang J, Tran H, Lee JJ, Gibbons D, Vaporciyan A, Heymach J, Lin C, Gottlieb E, You MJ, Welsh JW, Lin SH, Zang X, Li Z, Gan B

Nat Med. 2026 Jun 24. doi: 10.1038/s41591-026-04508-1.
Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, Xiong Y, Zhou C, Yang H, Liu L, Dai J, Zou N, Xu S, Wang Y, Wang Z, Deng J, Chen X, Wang J, Xiang H, Li X, Duchemann B, Chen G, Xia Y, Mok T, Scheiermann C, Lévi F, Yang N, Zhang Y

Nature. 2026 Jun 24. doi: 10.1038/s41586-026-10674-6.
Obermeyer Z, Schubert A, Ross J, Mullainathan S, Lingman M

Med Trop Sante Int. 2023 Jul 3;3(3):mtsi.v3i3.2023.396. doi: 10.48327/mtsi.v3i3.2023.396. eCollection 2023 Sep 30.
Elien Gagnan Yan Zaou Tou RR, Mbaïkoua JM, Kosh Komba Palet JE, Guirou N

N Engl J Med. 2026 Jun 25;394(24):2440-2448. doi: 10.1056/NEJMoa2518035.
Ruella M, Paruzzo L, Chong ER, Chong EA, Landsburg DJ, Nasta SD, Devi P, Michener P, Stella F, Carturan A, Napier EB, Van Deerlin VM, Porazzi P, Levine BL, Frey N, Porter DL, Fraietta JA, Svoboda J, June CH, Schuster SJ

Cell. 2026 Jun 25;189(13):3871-3882.e12. doi: 10.1016/j.cell.2026.06.002.
Baker DJ, Frommer LM, Uslu U, Patel KK, Zhu D, Engel NW, George JM, Zhao W, Kim SI, Sun L, Roselle C, Rommel PC, Young RM, Epstein JA, Hayat S, Arany Z, June CH

Cancer Discov. 2026 Jun 24. doi: 10.1158/2159-8290.CD-25-0806.
Huang J, Chen Y, Deng P, Kong Q, Lin K, Li Y, Li Y, Fu C, Deng W, Xv J, Wei B, Kuang DM, Cai J, Jin J, Tian R, Lu Y, Su S

Nature. 2026 Jun 24. doi: 10.1038/s41586-026-10685-3.
Zhang B, Xu P, Meng Y, Gallay L, Lestelle F, Morel H, Frémond ML, Correia BE, Ablasser A

J Nutr. 2018 Jun 1;148(6):861-867. doi: 10.1093/jn/nxy004.
Holscher HD, Guetterman HM, Swanson KS, An R, Matthan NR, Lichtenstein AH, Novotny JA, Baer DJ

JAMA Netw Open. 2026 Jun 1;9(6):e2625152. doi: 10.1001/jamanetworkopen.2026.25152.
Wiegand RE, Chickery S, Yang DH, Ball SW, DeSilva MB, Dascomb K, Irving SA, Natarajan K, Klein NP, Grannis SJ, Ong TC, Rowley EAK, Yates A, Zhuang Y, Wilson S, McEvoy CE, Essien IJ, Akinsete OO, Naleway AL, Koppolu P, Zerbo O, Hansen JR, Jacobson KB, Block L, Dixon BE, Duszynski T, Rogerson C, Barron MA, Chavez C, Mak J, Ciesla AA, Godfrey M, Kautz A, Najdowski M, Link-Gelles R, DeCuir J, Payne AB

Nature. 2026 Jun 24. doi: 10.1038/s41586-026-10697-z.
Feng X, Zhang S, Wang Y, Kurlagunda T, Sit A, Jaishankar P, Yang P, Sakane S, Park SY, Wisessaowapak C, Nguyen K, Yan J, Pothulu H, Dinh C, Chu F, Ren Y, Zhang B, Secrest P, Han L, Hung CW, Veeragandham P, Skorobogatko Y, Kisseleva T, Gordts PLSM, Renslo AR, Zhao P, Majithia AR, Saltiel AR

Cell Metab. 2026 Jun 24:S1550-4131(26)00226-3. doi: 10.1016/j.cmet.2026.05.016.
Du W, Xu JY, Li Y, Zhang M, Huang Y, Zhao S, Zhou Y, Zhao L, Xu K, Zhai L, Zhao W, Liu J, Ni J, Dai J, Liu T, Hong J, Jiang H, Zhao S, Zhang J, Zhou L, Wang JQ, Yin BC, Liu RX, Li J, Ye BC, Tan M

Lancet. 2026 Jun 24:S0140-6736(26)00983-9. doi: 10.1016/S0140-6736(26)00983-9.
Huang H, Xu S, Qin T, Wang M, Li G, Liu C, Deng G, Wang Y, Ao D, Xie Y, Zhang Y, Kong Q, Lan L, Yu Y, Huang S, Yu Z, Yi T, Chen W, Zhao W, Su J, Zhou P, Li F, Mei B, Jing P, Zhang J, Du J, Goyal M, Nguyen TN, Wang D, Saver JL, Tang Z, Wang W, Luo X; ATTRACTION Investigators

Neuroimage. 2012 Sep;62(3):1415-28. doi: 10.1016/j.neuroimage.2012.05.050. Epub 2012 May 24.
Stam CJ, van Straaten EC

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:57-63.
Wasaburo K, Tanabe S, Higuchi K, Sasaki T, Nakayama N, Mihara S, Nakatani K, Nishimura K, Shimoda T, Azuma M, Katada C, Hanaoka N, Naruke A, Ryu T, Ishido K, Saigenji K

Nature. 2026 Jun 24. doi: 10.1038/s41586-026-10678-2.
Tsour S, Machné R, Leduc A, Widmer S, Koo E, Guez J, Karczewski KJ, Slavov N

Nature. 2026 Jun 24. doi: 10.1038/s41586-026-10683-5.
Kahsai AW, Pakharukova N, Kwon HY, Shah KS, Del Real CT, Shreiber BN, Liang-Lin JG, Shim PJ, Lee MA, Ngo VA, Schwalb AM, Pham U, Chundi A, Jiang H, Flores-Espinoza E, Liu S, Nibley PC, Bassford DK, Hahn H, Kunzle CA, Thomas BN, Kim J, Zhou Y, Wang J, Zhang X, Smith JS, Rein LAM, Thomsen ARB, Shenoy SK, Rajagopal S, Shi L, Ahn S, Rockman HA, Masoudi A, Lefkowitz RJ

Cell Metab. 2026 Jun 23:S1550-4131(26)00225-1. doi: 10.1016/j.cmet.2026.05.015.
Fanti M, Brandhorst S, Navarrete G, Diaz A, Giuliani G, Chowdhury D, Antunes GC, Morgan TE, Dubeau L, Villani V, Perin L, Malik VS, Hu FB, Longo VD